Predicting response to neoadjuvant therapy with glucose transporter-1 in breast cancer.

Creative Commons License

Öztürk S. D., Öztürk Ç., Okcu O., Aşkan G., Şen B., Bedir R.

Revista da Associacao Medica Brasileira (1992), vol.69, no.3, pp.440-446, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 69 Issue: 3
  • Publication Date: 2023
  • Doi Number: 10.1590/1806-9282.20221334
  • Journal Name: Revista da Associacao Medica Brasileira (1992)
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.440-446
  • Keywords: Glucose transporter type 1, Breast, Cancer, Immunohistochemistry, Neoadjuvant therapy, GLUCOSE-TRANSPORTER, POOR-PROGNOSIS, GLUT-1, OVEREXPRESSION, EXPRESSION, KI-67, ADENOCARCINOMA, PROLIFERATION
  • Recep Tayyip Erdoğan University Affiliated: Yes


OBJECTIVE: Glucose transporter-1 is a marker involved in energy transport in cancer cells. It has been shown to be a poor prognostic factor in many cancer types, including breast cancer. However, there is no satisfactory parameter predicting treatment in breast cancer patients receiving neoadjuvant therapy. This study investigated the effect of glucose transporter-1 in predicting the treatment response of patients receiving neoadjuvant therapy. METHODS: In this study, glucose transporter-1 immunohistochemistry was applied to tru-cut biopsy of patients who were diagnosed with breast cancer and received neoadjuvant therapy between 2010 and 2021. A built-in scoring system was used to evaluate both the pattern and intensity of glucose transporter-1 immunohistochemistry staining. The relationship between glucose transporter-1 immunohistochemistry staining and other clinicopathological parameters was examined. In addition, the relationship of glucose transporter-1 with response to treatment was investigated.RESULTS: A relationship was found between high glucose transporter-1 expression and other clinicopathological parameters (such as estrogen and progesterone receptor negativity, high Ki-67, triple-negative, and Her2 status). Cases with high glucose transporter-1 expression had either a complete or a partial pathologic response. The result was statistically significant. CONCLUSION: Glucose transporter-1 has the potential to be a biomarker that can be evaluated more objectively as an alternative to Ki-67 labeling index in evaluating the response to treatment in patients receiving neoadjuvant therapy.